Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 824)
Technische Universität München
Received: 11 June 2021
Accepted: 28 July 2021
First Online: 16 August 2021
: This study was approved by our local ethics committee (284/16S) and performed in accordance with the 1964 Helsinki declaration and its later amendments.
: Informed consent was obtained from all individual participants included in this study.
: Claus Zimmer: has served on scientific advisory boards for Philips and Bayer Schering; has received speaker honoraria from Bayer-Schering and Philips and has received research support and investigator fees for clinical studies from Biogen Idec, Quintiles, MSD Sharp and Dome, Boehringer Ingelheim, Inventive Health Clinical UK Ltd., Advance Cor, Brainsgate, Pfizer, Bayer Schering, Novartis, Roche, Servier, Penumbra, WCT GmbH, Syngis, SSS International Clinical Research, PPD Germany GmbH, Worldwide Clinical Trials Ltd., Phenox, Covidien, Actelion, Medivation, Medtronic, Harrison Clinical Research, Concentric, Penumbra, Pharmtrace, Reverse Medical Corp., Premier Research Germany Ltd., Surpass Medical Ltd. and GlaxoSmithKline. Benedikt Wiestler: has received speaker honoraria from Bayer AG. All other authors declare that they have no conflicts of interest.